1. Lloyd-Jones D, Adams R, Carnethon M et al.; for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 119: e1–161.
2. http://www.heartstats.org/latestadditions.asp?id=83.
3. Laurent S, Cockcroft J, Van Bortel L et al. for the European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588–605.
4. Nilsson PM, Lurbe E, Laurent S. The early life origins of vascular ageing and cardiovascular risk: the EVA syndrome [review]. J Hypertens 2008; 26: 1049–57.
5. Nilsson PM, Boutouyrie P, Laurent S. Vascular Aging: A Tale of EVA and ADAM in Cardiovascular Risk Assessment and Prevention. Hypertension 2009; 54; 3–10.
6. Kannel WB, Wolf PA, McGee DL et al. Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study. JAMA 1981; 245: 1225–9.
7. Safar ME, Levy BI, London GM. Arterial structure in hypertension and the effects of angiotensin converting enzyme inhibition. J Hypertens 1992; 10 (Suppl. 5): S51–7.
8. Safar ME. Pulse pressure in essential hypertension: clinical and therapeutical implication. J Hypertens 1989; 7: 769–76.
9. Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23: 395–401.
10. Henskens LH, Kroon AA, van Oostenbrugge RJ et al. Increased aortic pulse wave velocity is associated with silent cerebral small-vessel disease in hypertensive patients. Hypertension 2008; 52: 1120–6.
11. Hanon O, Haulon S, Lenoir H et al. Relationship between arterial stiffness and cognitive function in elderly subjects with complaints of memory loss. Stroke 2005; 36: 2193–7.
12. Scuteri A, Tesauro M, Appolloni S et al. Arterial stiffness as an independent predictor of longitudinal changes in cognitive function in the older individual. J Hypertens 2007; 25: 1035–40.
13. Williams В, Lacy PC. Central aortic pressure and clinical outcomes. J Hypertens 2009; 27: 1123–5.
14. Safar M. Effect of angiotensin II blockade on central blood pressure and arterial stiffness in subjects with hypertension. Int J Nephrol Renovasc Dis 2010; 3: 167–73.
15. Agabiti-Rosei E, Mancia G, O’Rourke MF et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension 2007; 50: 154–60.
16. Boutouyrie P, Tropeano AI, Asmar R et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002; 39: 10–5.
17. Laurent S, Boutouyrie P. Recent advances in arterial stiffness and wave reflection in human hypertension: hypertension highlights. Hypertension 2007; 49: 1202–6.
18. Heangerty A, Bund S, Aaikar C. Effects of drug treatment on human resistance arteriole morphology in essential hypertension: direct evidence for structural remodeling of resistance vessels. Lancet 1988; p. 1209–12.
19. Aaikar C, Eiskjar H, Mulvany M et al. Abnormal structure and function of isolated subcutaneous resistance vessels from essential hypertensive patients despite antihypertensive treatment. J Hypertens 1989; 7: 305–10.
20. Schiffrin E, Deng L, Larochelle P. Effect of beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 1994; 23: 83–91.
21. Sihm I, Schroeder AP, Aalkjaer C et al. Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-Inhibitor perindopril. Blood Press 1995; 4: 241–8.
22. London GM, Asmar RG, O’Rourke MF, Safar ME; on behalf of the REASON project. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: Comparison with atenolol. J Am Coll Cardiol 2004; 43 (1): 92–9.
23. Dahlöf B, Sever PS, Poulter NR; for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.
24. Staessen JA, Birkenhäger WH. Evidence that new antihypertensives are superior to older drugs. Lancet 2005 [DOI: 10.1016/50140-6736(05)67147-4].
25. The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators. Differential Impact of Blood Pressure–Lowering Drugs on Central Aortic Pressure and Clinical Outcomes Principal Results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation 2006; 113: NA.
26. Poulter NR, Wedel H, Dahlöf B et al.; for the ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907–13.
27. Thybo NK, Korsgaard N, Eriksen S et al. Dose-dependent effects of perindopril on blood pressure and small-artery structure. Hypertension 1994; 23: 659–66.
28. Mackenzie I et al. Comparison of the Effects of Antihypertensive Agents on Central Blood Pressure and Arterial Stiffness in Isolated Systolic Hypertension. Hypertension 2009; 54: 409–13.
29. Tropeano AI. Brachial Pressure-Independent Reduction in Carotid Stiffness After Long-Term Angiotensin-Converting Enzyme Inhibition in Diabetic Hypertensives. Hypertension 2006; 48: 80–6.
30. Nedogoda SV et al Randomized Trial of Perindopril, Enalapril, Losartan and Telmisartan in Overweight or Obese Patients with Hypertension. Clin Drug Investig 2013.
31. Williams B, Lacy PS, Cruickshank JK et al. Impact of Statin Therapy on Central Aortic Pressures and Hemodynamics Principal Results of the Conduit Artery Function Evaluation-Lipid Lowering Arm (CAFE-LLA) Study. Circulation 2009; 119: 53–61.
32. Manisty С, Mayet J, Tapp RJ et al.; on behalf of the ASCOT Investigators. Atorvastatin Treatment Is Associated With Less Augmentation of the Carotid Pressure Waveform in Hypertension A Substudy of the Anglo-Scandinavian Cardiac Outcome Trial 
(ASCOT). Hypertension 2009; 54.
33. Sever PS, Dahlof B, Poulter NR et al.; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58.
34. EUROPA Study Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
35. Ceconi C et al. J Hypertens 2005; 23 (Suppl. 2): S274.
36. Zethelius B, Berglund L, Sundstrom J et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107–16.

Ю.В.Котовская, Е.А.Троицкая, Ж.Д.Кобалава

ФГБОУ ВПО Российский университет дружбы народов, Москва